LEXX
Lexaria Bioscience Corp.
Biotechnology
Market Cap$14M
5Y Perf.-86.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LEXX vs CMPS
Revenue, margins, valuation, and 5-year total return — side by side.
CMPS
COMPASS Pathways plc
Medical - Care Facilities
Market Cap$902M
5Y Perf.-78.6%
LEXX vs CMPS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LEXX | CMPS |
|---|---|---|
| Industry | Biotechnology | Medical - Care Facilities |
| Market Cap | $14M | $902M |
| Revenue (TTM) | $522K | $0.00 |
| Net Income (TTM) | $-11M | $-288M |
| Gross Margin | 84.9% | — |
| Operating Margin | -20.2% | — |
| Total Debt | $109K | $21M |
| Cash & Equiv. | $2M | $150M |
LEXX vs CMPS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LEXX
CMPS
| Stock | Jan 21 | May 26 | Return |
|---|---|---|---|
| Lexaria Bioscience … (LEXX) | 100 | 13.8 | -86.2% |
| COMPASS Pathways plc (CMPS) | 100 | 21.4 | -78.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LEXX vs CMPS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CMPS leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Lexaria Bioscience Corp. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
LEXX
Lexaria Bioscience Corp.
The Income Pick
LEXX is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.00
- Lower volatility, beta 1.00, Low D/E 4.2%, current ratio 2.32x
- Beta 1.00, current ratio 2.32x
Best for: income & stability and sleep-well-at-night
CMPS
COMPASS Pathways plc
The Growth Play
CMPS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth -33.9%
- -67.6% 10Y total return vs LEXX's -85.7%
- 1.3% margin vs LEXX's -20.7%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LEXX | 52.0% revenue growth vs CMPS's -85.7% |
| Quality / Margins | CMPS | 1.3% margin vs LEXX's -20.7% |
| Stability / Safety | LEXX | Beta 1.00 vs CMPS's 1.33 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CMPS | +151.1% vs LEXX's -38.4% |
| Efficiency (ROA) | CMPS | -106.8% ROA vs LEXX's -178.4% |
LEXX vs CMPS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
LEXX vs CMPS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLEXXLAGGINGCMPS
CMPSCOMPASS Pathways plc
2leads
LEXXLexaria Bioscience Co…
2leads
6 Total Categories
CATEGORYLEADERvs CMPSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LEXX1/1
Valuation MetricsMultiples, price ratios, and targets
CMPS1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
LEXX4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
CMPS6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LEXX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
LEXX and CMPS operate at a comparable scale, with $522,000 and $0 in trailing revenue.
| Metric | LEXXLexaria Bioscienc… | CMPSCOMPASS Pathways … |
|---|---|---|
| RevenueTrailing 12 months | $522,000 | $0 |
| EBITDAEarnings before interest/tax | -$10M | -$179M |
| Net IncomeAfter-tax profit | -$11M | -$288M |
| Free Cash FlowCash after capex | -$9M | -$157M |
| Gross MarginGross profit ÷ Revenue | +84.9% | — |
| Operating MarginEBIT ÷ Revenue | -20.2% | — |
| Net MarginNet income ÷ Revenue | -20.7% | — |
| FCF MarginFCF ÷ Revenue | -16.7% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +53.4% | -58.7% |
LEXX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
CMPS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | LEXXLexaria Bioscienc… | CMPSCOMPASS Pathways … |
|---|---|---|
| Market CapShares × price | $14M | $902M |
| Enterprise ValueMkt cap + debt − cash | $13M | $774M |
| Trailing P/EPrice ÷ TTM EPS | -0.97x | -3.05x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 20.17x | — |
| Price / BookPrice ÷ Book value/share | 4.43x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
CMPS leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
LEXX leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
LEXX delivers a -2.4% return on equity — every $100 of shareholder capital generates $-2 in annual profit, vs $-3 for CMPS. On the Piotroski fundamental quality scale (0–9), LEXX scores 3/9 vs CMPS's 2/9, reflecting mixed financial health.
| Metric | LEXXLexaria Bioscienc… | CMPSCOMPASS Pathways … |
|---|---|---|
| ROE (TTM)Return on equity | -2.4% | -3.4% |
| ROA (TTM)Return on assets | -178.4% | -106.8% |
| ROICReturn on invested capital | -7.9% | — |
| ROCEReturn on capital employed | -2.2% | -2.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.04x | — |
| Net DebtTotal debt minus cash | -$2M | -$129M |
| Cash & Equiv.Liquid assets | $2M | $150M |
| Total DebtShort + long-term debt | $109,320 | $21M |
| Interest CoverageEBIT ÷ Interest expense | — | -52.40x |
LEXX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
CMPS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CMPS five years ago would be worth $2,756 today (with dividends reinvested), compared to $1,023 for LEXX. Over the past 12 months, CMPS leads with a +151.1% total return vs LEXX's -38.4%. The 3-year compound annual growth rate (CAGR) favors CMPS at 3.5% vs LEXX's -14.4% — a key indicator of consistent wealth creation.
| Metric | LEXXLexaria Bioscienc… | CMPSCOMPASS Pathways … |
|---|---|---|
| YTD ReturnYear-to-date | -2.0% | +43.4% |
| 1-Year ReturnPast 12 months | -38.4% | +151.1% |
| 3-Year ReturnCumulative with dividends | -37.2% | +11.0% |
| 5-Year ReturnCumulative with dividends | -89.8% | -72.4% |
| 10-Year ReturnCumulative with dividends | -85.7% | -67.6% |
| CAGR (3Y)Annualised 3-year return | -14.4% | +3.5% |
CMPS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — LEXX and CMPS each lead in 1 of 2 comparable metrics.
Risk & Volatility
LEXX is the less volatile stock with a 1.00 beta — it tends to amplify market swings less than CMPS's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CMPS currently trades 92.0% from its 52-week high vs LEXX's 41.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LEXXLexaria Bioscienc… | CMPSCOMPASS Pathways … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.00x | 1.33x |
| 52-Week HighHighest price in past year | $1.55 | $10.21 |
| 52-Week LowLowest price in past year | $0.46 | $2.25 |
| % of 52W HighCurrent price vs 52-week peak | +41.3% | +92.0% |
| RSI (14)Momentum oscillator 0–100 | 36.1 | 68.1 |
| Avg Volume (50D)Average daily shares traded | 180K | 3.7M |
Evenly matched — LEXX and CMPS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | LEXXLexaria Bioscienc… | CMPSCOMPASS Pathways … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $17.83 |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
LEXX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CMPS leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Best OverallLexaria Bioscience Corp. (LEXX)Leads 2 of 6 categories
Loading custom metrics...
LEXX vs CMPS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is LEXX or CMPS a better buy right now?
Analysts rate COMPASS Pathways plc (CMPS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LEXX or CMPS?
Over the past 5 years, COMPASS Pathways plc (CMPS) delivered a total return of -72.
4%, compared to -89. 8% for Lexaria Bioscience Corp. (LEXX). Over 10 years, the gap is even starker: CMPS returned -67. 6% versus LEXX's -85. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LEXX or CMPS?
By beta (market sensitivity over 5 years), Lexaria Bioscience Corp.
(LEXX) is the lower-risk stock at 1. 00β versus COMPASS Pathways plc's 1. 33β — meaning CMPS is approximately 33% more volatile than LEXX relative to the S&P 500.
04Which is growing faster — LEXX or CMPS?
On earnings-per-share growth, the picture is similar: COMPASS Pathways plc grew EPS -33.
9% year-over-year, compared to -40. 4% for Lexaria Bioscience Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LEXX or CMPS?
COMPASS Pathways plc (CMPS) is the more profitable company, earning 0.
0% net margin versus -1686. 0% for Lexaria Bioscience Corp. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CMPS leads at 0. 0% versus -1648. 0% for LEXX. At the gross margin level — before operating expenses — LEXX leads at 83. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — LEXX or CMPS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is LEXX or CMPS better for a retirement portfolio?
For long-horizon retirement investors, Lexaria Bioscience Corp.
(LEXX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00)). Both have compounded well over 10 years (LEXX: -85. 7%, CMPS: -67. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between LEXX and CMPS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: LEXX is a small-cap high-growth stock; CMPS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.